Mydecine Innovations Group Past Earnings Performance
Past criteria checks 0/6
Mydecine Innovations Group's earnings have been declining at an average annual rate of -6.3%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been declining at an average rate of 70.4% per year.
Key information
-6.3%
Earnings growth rate
77.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -70.4% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Mydecine Innovations Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -18 | 12 | 2 |
| 30 Jun 23 | 0 | -20 | 13 | 2 |
| 31 Mar 23 | 0 | -19 | 13 | 3 |
| 31 Dec 22 | 0 | -17 | 13 | 4 |
| 30 Sep 22 | 0 | -23 | 15 | 4 |
| 30 Jun 22 | 0 | -18 | 16 | 4 |
| 31 Mar 22 | 0 | -24 | 17 | 5 |
| 31 Dec 21 | 0 | -24 | 18 | 4 |
| 30 Sep 21 | 0 | -19 | 12 | 3 |
| 30 Jun 21 | 0 | -37 | 14 | 3 |
| 31 Mar 21 | 0 | -32 | 14 | 2 |
| 31 Dec 20 | 0 | -27 | 10 | 1 |
| 30 Sep 20 | 0 | -39 | 9 | 0 |
| 30 Jun 20 | 0 | -23 | 5 | 0 |
| 31 Mar 20 | 0 | -20 | 2 | 0 |
| 31 Dec 19 | 0 | -21 | 3 | 0 |
| 30 Sep 19 | 0 | -5 | 5 | 0 |
| 30 Jun 19 | 0 | -5 | 5 | 0 |
| 31 Mar 19 | 0 | -11 | 6 | 0 |
| 31 Dec 18 | 0 | -13 | 6 | 0 |
| 30 Sep 18 | 0 | -22 | 12 | 0 |
| 30 Jun 18 | 0 | -21 | 11 | 0 |
| 31 Mar 18 | 0 | -18 | 13 | 0 |
| 31 Dec 17 | 0 | -18 | 15 | 0 |
| 30 Sep 17 | 0 | -14 | 10 | 0 |
| 30 Jun 17 | 0 | -14 | 10 | 0 |
| 31 Mar 17 | 0 | -11 | 7 | 0 |
| 31 Dec 16 | 0 | -8 | 4 | 0 |
| 30 Sep 16 | 0 | -1 | 1 | 0 |
| 30 Jun 16 | 0 | -1 | 1 | 0 |
| 31 Mar 16 | 0 | -3 | 3 | 0 |
| 31 Dec 15 | 0 | -4 | 4 | 0 |
| 30 Sep 15 | 0 | -4 | 4 | 0 |
| 30 Jun 15 | 0 | -4 | 4 | 0 |
| 31 Mar 15 | 0 | -2 | 1 | 0 |
| 31 Dec 14 | 0 | -1 | 1 | 0 |
| 30 Sep 14 | 0 | -1 | 0 | 0 |
| 31 Mar 14 | 0 | 0 | 0 | 0 |
| 31 Dec 13 | 0 | 0 | 0 | 0 |
Quality Earnings: 0NF0 is currently unprofitable.
Growing Profit Margin: 0NF0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0NF0 is unprofitable, and losses have increased over the past 5 years at a rate of 6.3% per year.
Accelerating Growth: Unable to compare 0NF0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0NF0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 0NF0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.